Acumen Pharmaceuticals, Inc.
NASDAQ:ABOSBiotechnology
+$0.02 today
- Market cap
- $165.63M
- Beta
- 0.35
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.79
Volume 0.81M
Average 0.40M
ABOS Net Income
Bottom-line profit after all expenses, interest, and taxes.
Acumen Pharmaceuticals, Inc.NASDAQ: ABOS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$20.74M, compared with -$28.8M a year earlier. Trailing-twelve-month net income was -$113.28M.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$90.1M (+25.7%) for the fiscal year ending Dec 2026, a step up from the -18.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$20.74M+17.5% QoQ
- Last fiscal yearDec 2025
- -$121.34M-18.6% YoY
- LTMMar 2026
- -$113.28M+2.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +28.0% | +44.5% | +16.5 pp |
| 1 year | -18.6% | +25.7% | +44.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (121.34M) USD
- Year-over-year change
- -18.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (121.34M) | -18.6% |
| FY2024 | 2024-12-31 | (102.33M) | -95.4% |
| FY2023 | 2023-12-31 | (52.37M) | -22.2% |
| FY2022 | 2022-12-31 | (42.86M) | +57.4% |
| FY2021 | 2021-12-31 | (100.61M) | — |
Net Income vs competitors
How ABOS compares with its peers on the latest reported figures
- ABOS's LTM Mar 2026 net income of -$113.28M is the 8th highest of the 10 companies compared; the peer median is -$70.49M.
- Its year-over-year change of +2.6% is the 7th highest of 10, against a peer median of +14.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $64.61M | +133.9% | — | 52.2% | |
| LTM Mar 2026 | $15.24M | +121.8% | — | 27.8% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | -$21.54M | +14.9% | — | — |
| LTM Mar 2026 | -$46.9M | -164.3% | — | 4088.8% | |
| LTM Mar 2026 | -$70.49M | +17.9% | — | 468.7% | |
| LTM Mar 2026 | -$84.93M | +12.0% | — | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$106.93M | -82.4% | — | 892.4% |
| LTM Mar 2026 | -$113.28M | +2.6% | — | — | |
| LTM Mar 2026 | -$125.39M | -1.6% | — | 680.8% | |
| LTM Mar 2026 | -$129.91M | +26.1% | — | 2056.8% | |
| Peer median (excluding ABOS) | -$70.49M | +14.9% | — | 680.8% | |
Competitors are the stored peer set for ABOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 12.31M | 0 | 0 | 0 | 0 |
| Gross Profit | (12.31M) | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 12.31M | 32.36M | 42.32M | 93.8M | 104.89M |
| Selling, General & Admin | 7.28M | 12.88M | 18.82M | 20.22M | 18.95M |
| Operating Expenses | 7.28M | 45.24M | 61.14M | 114.02M | 123.83M |
| Depreciation & Amortization | 4K | 169K | 184K | 178K | 184K |
| EBITDA | (100.6M) | (42.69M) | (51.61M) | (98.08M) | (116.93M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (19.58M) | (45.24M) | (61.14M) | (114.02M) | (123.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 84K | 2.39M | 10.79M | 14.32M | 7.45M |
| Interest Expense | 0 | 0 | 581K | 4.07M | 4.22M |
| Other Income / Expenses | (81.02M) | 2.38M | 8.77M | 11.69M | 2.5M |
| Income Before Tax | (100.61M) | (42.86M) | (52.37M) | (102.33M) | (121.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (100.61M) | (42.86M) | (52.37M) | (102.33M) | (121.34M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.63) | (1.06) | (1.08) | (1.71) | (2.00) |
| EPS (Diluted) | (2.63) | (1.06) | (1.08) | (1.71) | (2.00) |
| Weighted Avg Shares | 38.27M | 40.6M | 48.49M | 60.01M | 60.56M |
| Weighted Avg Shares (Diluted) | 38.27M | 40.6M | 48.61M | 60.01M | 60.56M |
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
Intrinsic Alpha fair value
Locked
Current Price
$2.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.